OncologyTube Professional - Patients Click Here
210,218 video views
obr: Videos
02:09
Al Benson III, MD, FACP, explains how tumor-sidedness impacts colorectal cancer treatment algorithms at ASCO 2018.
by:obr | 2 views
01:04
Robert A. Figlin, MD, explains the trade-offs between safety and efficacy when discussing first-line renal cell carcinoma (RCC) treatment options.
by:obr | 3 views
00:39
Bobby Green, MD, explains Flatiron's clinico-genomic database helping shed light on the cost-effectiven​ess of next-generation sequencing at ASCO 2018.
by:obr | 2 views
01:08
Roy S. Herbst, MD, PhD, shares his thoughts on whether Keynote 189 impacted view of PDL-1 expression and patient selection at ASCO 2018.
by:obr | 7 views
01:01
Celestia S. Higano, MD, shares the outcomes from the PROSPER and SPARTAN studies in non-metastatic castrate-resist​ant prostate cancer are impacting the standard of care at ASCO 2018
by:obr | 4 views
00:40
Edgardo S. Santos, MD, FACP, shares his opinion on continued pemetrexed maintenance at ASCO 2018
by:obr | 4 views
00:15
Joan Schiller, MD, shares her opinion on continuing pemetrexed maintenance after successful treatment with carboplatin, pemetrexed & pembrolizumab
by:obr | 2 views
00:51
Robert A. Figlin, MD, talks about the best actions to take if newly diagnosed advanced renal cell carcinoma (RCC) patients receive nivolumab & ipilimumab but continues to progress at ASCO 2018.
by:obr | 2 views
03:00
Al Benson III, MD, FACP, explains the role of I-O and immunotherapy when treating colorectal cancer at ASCO 2018
by:obr | 3 views
01:04
Bobby Green, MD, explains Flatiron’s clinico-genomic database and how it may be used to direct treatments at ASCO 2018.
by:obr | 3 views
dsfsd